FOSTER CITY, Calif., August 29, 2001--Cell Genesys, Inc. (Nasdaq: CEGE) today announced that Peter K. Working, Ph.D., has joined the company in the new position of vice president, research and development.Dr. Working, who served most recently as vice president of analytical and non-clinical sciences and principal scientist at ALZA Corporation, brings over 20 years of pharmaceutical research and development experience to Cell Genesys including 13 years in the biotechnology industry.Dr. Working
, who will report to Joe Vallner, Ph.D., president and chief operating officer, was, in the past, a key member of Dr. Vallner's team at SEQUUS Pharmaceuticals--a team which successfully developed and launched pharmaceutical products including the cancer product, Doxil®.
"We are delighted to have Peter
join our executive team and believe that Peter's extensive experience in biopharmaceutical product development will prove to be invaluable as we continue to advance multiple product programs into Phase III clinical trials over the next eighteen months," stated Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys
...Dr. Working, 53, previously with ALZA Corporation, has also held various positions with SEQUUS Pharmaceuticals, where he served as vice president of research and development, as well as Genentech, Inc. where he served as a senior toxicologist and head of the Experimental Toxicology Group in the Department of Safety Evaluation.Dr. Working holds Ph.D., M.S. and B.S. degrees from the University of California, Davis and the University of California, San Francisco. Cell Genesys
is focused on the development and commercialization of cancer vaccines and gene therapies to treat major, life-threatening diseases.The company is conducting clinical trials of GVAX® cancer vaccines in prostate cancer, lung cancer, pancreatic cancer and myeloma and expects to initiate new studies in acute leukemia during 2001.Preclinical stage programs include gene therapies for cancer, hemophilia and cardiovascular disorders.Cell Genesys'
majority-owned subsidiary, Ceregene, is focused on gene therapies for central nervous system disorders.Cell Genesys
also continues to hold a 10.5 percent equity interest in its former subsidiary, Abgenix
, an antibody product company.Additionally, on August 2, 2001, Cell Genesys
announced that it entered into a definitive agreement, expected to close in 30 days, for the acquisition of Calydon, Inc.
, a private biotechnology company focused on developing therapeutic products for cancer.